Metabolic dysfunction-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease and often referred to as fatty liver disease, affects nearly 30% of adults worldwide.
It is one of the most prevalent chronic liver conditions, yet despite its scale it is still too often misdiagnosed, misunderstood or mistreated, delaying meaningful intervention for millions.
For decades, MASLD has been described as a ‘silent’ condition because it rarely presents with dramatic liver specific symptoms early on. Instead, it hides in plain sight, embedded within metabolic dysfunction and everyday complaints that are easy to attribute elsewhere.
Check out the rest of the feature here
